- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
Lilly has a rich pipeline with a number of marketed medicines including oncology and diabetes. Quantitative pharmacology (model-based decision making) has been widely used and applied throughout different stages of drug development at Lilly.
Lilly staff will provide expertise in relevant therapeutic areas, drug development process and methodology issues needed by the project. The three PIs involved in the project are experts in the field of modelling and simulation in pharmacology and have practical experience in clinical trial designs and PK/PD analysis. In particular they are recognised authorities in oncology and optimal design.